Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-CD19 iCAR NK Cells in Relapsed and Refractory B Cell Lymphoma
NCT03824951Phase 1Unknown
- Sponsor
- Allife Medical Science and Technology
- Start
- Feb 2019
- Primary completion
- Jan 2020
- Modality
- Patient-derived iPSCs, Lymphokine-Activated Killer Cells, Allogeneic iPSCs
01
Overview
Phase 1, open-label, single-arm trial of CD19 iCAR-NK in B cell lymphoma, sponsored by Allife Medical Science and Technology. Primary endpoint: Occurrence of treatment related adverse events as assessed by CTCAE v4.0 at 1 year. Status: unknown.
02
Drugs
CD19 iCAR-NK
03
Conditions
B cell lymphoma
Beyond the preview
Go deeper on NCT03824951.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03824951.